



Novartis Animal Health US, Inc.

Passionately saving, prolonging, and improving animal lives

U.S. Animal Health Headquarters: 3200 Northline Ave., Ste. 300, Greensboro, NC 27408

U.S. Animal Health CEO: Robert Jones

Companion Animal Business

U.S. Companion Animal Vice President of Sales: Adrian Pountain

U.S. Companion Animal Vice President of Marketing: Richard Hart

Web Site Address: www.petwellness.com (please see Web site for complete product information)

Key Products	Description
Interceptor®	Once-a-month oral broad-spectrum chewable tablet prevents heartworm disease, and removes and/or controls major intestinal parasites in dogs and cats, including roundworms, hookworms and whipworms
Sentinel®	The only monthly oral preventive that guards against five parasites (fleas, heartworms, roundworms, hookworms and whipworms)
Deramaxx®	This oral chewable tablet helps control chronic osteoarthritis pain and inflammation in dogs
Ethicon Products	Synthetic, absorbable sutures provide minimal tissue trauma and predictable wound support during the healing process
Atopica®	This soft, oral capsule is used to control atopic dermatitis in dogs
Program®	Oral tablets for dogs and cats prevent flea eggs and larvae from developing
Capstar®	A single-dose oral tablet starts to kill adult fleas on cats and dogs within 30 minutes
Clomicalm®	The only medication approved for treating separation anxiety in dogs comes in an oral tablet
MilbeMite™	Ear mite solution kills 99 percent of infestations in seven to 30 days

Farm Animal Business

Other U.S. Farm Animal Business Locations: 1447 140th St., Larchwood, IA 51241 (marketing services)
23805 Antioch Rd., Bucyrus, KS 66013 (custom vaccine facility)

U.S. Farm Animal Vice President of Sales and Marketing: Pedro Schmid

Web Site Address: www.livestock.novartis.com

Key Products	Description
Vira Shield®	Broad-spectrum BVD vaccine with protection against respiratory and reproductive diseases in cattle
Scour Bos®	Broad-spectrum calf scours vaccine administered to pregnant cows
Arsenal® 4.1	Modified live vaccine with protection against BVD, BRSV, IBR and PI ₃ in cattle
Clostridium Perfringens Type A Toxoid	Conditionally licensed vaccine for controlling disease syndromes caused by <i>Clostridium perfringens</i> Type A
Denagard®	Broad-spectrum antibiotic used to control and treat certain swine bacterial diseases, including dysentery and ileitis
PneumoSTAR® Myco	One-shot protection against mycoplasmal pneumonia
PneumoSTAR® SIV	One-shot prevention of swine influenza virus
Custom Vaccines	Designed exclusively for specific health problems

Research and Development

Novartis Animal Health US, Inc. is one of the industry leaders in the investment made in research and development projects and programs annually. Our goal is to develop innovative veterinary medicines and products that improve on current pet and livestock health programs or that address unmet medical needs in these areas. Innovation is the foundation of the Novartis R&D organization and is found both in the company's veterinary research laboratories and in the human pharmaceutical research arena. The company draws on the cutting-edge science being done at the Novartis Institutes of BioMedical Research in Cambridge, Mass., where there is a strong emphasis on biology of diseases and a strong commitment to external collaboration and strategic partnerships.

Research Collaborations – Novartis Animal Health works with leading public and private veterinary medical institutions, research facilities and companies to develop new generations of companion and farm animal health products.

Manufacturing Facilities – Novartis Animal Health utilizes a combination of corporate manufacturing capabilities and high-quality partners to produce, package and ship the full line of veterinary medicines made available throughout the United States.

Leading Worldwide Animal Health Companies 2004

